These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35982660)

  • 1. Viral and Symptom Rebound in Untreated COVID-19 Infection.
    Deo R; Choudhary MC; Moser C; Ritz J; Daar ES; Wohl DA; Greninger AL; Eron JJ; Currier JS; Hughes MD; Smith DM; Chew KW; Li JZ;
    medRxiv; 2022 Aug; ():. PubMed ID: 35982660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
    Deo R; Choudhary MC; Moser C; Ritz J; Daar ES; Wohl DA; Greninger AL; Eron JJ; Currier JS; Hughes MD; Smith DM; Chew KW; Li JZ;
    Ann Intern Med; 2023 Mar; 176(3):348-354. PubMed ID: 36802755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial.
    Yang Z; Xu Y; Zheng R; Ye L; Lv G; Cao Z; Han R; Li M; Zhu Y; Cao Q; Ding Y; Wang J; Tan Y; Liu F; Wei D; Tan W; Jiang W; Sun J; Sun S; Shao J; Deng Y; Gao W; Wang W; Zhao R; Qiu L; Chen E; Zhang X; Wang S; Ning G; Xu Y; Bi Y
    JAMA Netw Open; 2024 Mar; 7(3):e241765. PubMed ID: 38477921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated Individuals.
    Smith-Jeffcoat SE; Biddle JE; Talbot HK; Morrissey KG; Stockwell MS; Maldonado Y; McLean HQ; Ellingson KD; Bowman NM; Asturias E; Mellis AM; Johnson S; Kirking HL; Rolfes MAR; Olivo V; Merrill L; Battan-Wraith S; Sano E; McLaren SH; Vargas CY; Goodman S; Sarnquist CC; Govindaranjan P; Petrie JG; Belongia EA; Ledezma K; Pryor K; Lutrick K; Bullock A; Yang A; Haehnel Q; Rao S; Zhu Y; Schmitz J; Hart K; Grijalva CG; Salvatore PP
    Clin Infect Dis; 2024 May; 78(5):1175-1184. PubMed ID: 37963102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
    Edelstein GE; Boucau J; Uddin R; Marino C; Liew MY; Barry M; Choudhary MC; Gilbert RF; Reynolds Z; Li Y; Tien D; Sagar S; Vyas TD; Kawano Y; Sparks JA; Hammond SP; Wallace Z; Vyas JM; Barczak AK; Lemieux JE; Li JZ; Siedner MJ
    Ann Intern Med; 2023 Dec; 176(12):1577-1585. PubMed ID: 37956428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
    Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.
    Edelstein GE; Boucau J; Uddin R; Marino C; Liew MY; Barry M; Choudhary MC; Gilbert RF; Reynolds Z; Li Y; Tien D; Sagar S; Vyas TD; Kawano Y; Sparks JA; Hammond SP; Wallace Z; Vyas JM; Barczak AK; Lemieux JE; Li JZ; Siedner MJ
    medRxiv; 2023 Jun; ():. PubMed ID: 37425934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls.
    Pandit JA; Radin JM; Chiang DC; Spencer EG; Pawelek JB; Diwan M; Roumani L; Mina MJ
    Clin Infect Dis; 2023 Jul; 77(1):25-31. PubMed ID: 36810665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.
    Han J; Bae S; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Chang E; Kim SH
    Medicine (Baltimore); 2023 Sep; 102(39):e35094. PubMed ID: 37773854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
    Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY
    J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
    Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.
    Stankiewicz Karita HC; Dong TQ; Johnston C; Neuzil KM; Paasche-Orlow MK; Kissinger PJ; Bershteyn A; Thorpe LE; Deming M; Kottkamp A; Laufer M; Landovitz RJ; Luk A; Hoffman R; Roychoudhury P; Magaret CA; Greninger AL; Huang ML; Jerome KR; Wener M; Celum C; Chu HY; Baeten JM; Wald A; Barnabas RV; Brown ER
    JAMA Netw Open; 2022 Jan; 5(1):e2142796. PubMed ID: 35006245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
    Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial.
    Chew KW; Moser C; Daar ES; Wohl DA; Li JZ; Coombs R; Ritz J; Giganti M; Javan AC; Li Y; Malvestutto C; Klekotka P; Price K; Nirula A; Fischer W; Bala V; Ribeiro RM; Perelson AS; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM;
    medRxiv; 2021 Dec; ():. PubMed ID: 34981077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir.
    Wong GL; Yip TC; Lai MS; Wong VW; Hui DS; Lui GC
    JAMA Netw Open; 2022 Dec; 5(12):e2245086. PubMed ID: 36472873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.